Last year, 5 landmark trials demonstrated overwhelmingly that endovascular therapy improves outcome in early acute stroke with anterior large vessel occlusion. The low numbers needed to treat, ranging from 3 to 7 patients, compel us to rapidly translate these results into national and global practice.1,2 As investigators serially presented their findings at the 2015 American Heart Association/American Stroke Association (AHA/ASA)–sponsored International Stroke Conference, the audience erupted in uncharacteristic standing ovations. Finally we possessed a proven treatment for a devastating type of stroke. The lay press appropriately hailed the findings as a “game changer.”3